Cargando…
Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient
Hepatitis C virus (HCV) infection is known to affect long-term patient survivals. Elbasvir/grazoprevir (EBR/GZR) has shown a high cure rate in hemodialysis patients with HCV infection. However, the combination is rarely used in peritoneal dialysis patients. Herein, we report a case of successful tre...
Autores principales: | Chen, Jin, Li, Yi, Li, Guisen, Lei, Pu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178844/ https://www.ncbi.nlm.nih.gov/pubmed/32301365 http://dx.doi.org/10.1080/0886022X.2020.1753073 |
Ejemplares similares
-
Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
por: Zhdanov, Konstantin, et al.
Publicado: (2020) -
The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan
por: Tsai, Tzu‐Cheng, et al.
Publicado: (2019) -
Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection
por: Pijnenburg, Daniëlle W M, et al.
Publicado: (2020) -
The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study
por: Kumada, Hiromitsu, et al.
Publicado: (2016) -
Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients
por: Ji, Qinghua, et al.
Publicado: (2021)